Emmanouil Papasavvas, Livio Azzoni, Amélie Pagliuzza, Mohamed Abdel-Mohsen, Brian N Ross, Matthew Fair, Bonnie J Howell, Daria J Hazuda, Nicolas Chomont, Qingsheng Li, Karam Mounzer, Jay R Kostman, Pablo Tebas, Luis J Montaner
In the pilot NCT01935089 trial, we tested whether pegylated interferon alpha2b (Peg-IFN-α2b) with antiretroviral therapy (ART) was safe and could impact HIV and immune measures in blood and in gut-associated lymphoid tissue (GALT). Twenty HIV-1+ ART-suppressed individuals received 1 μg/kg/week Peg-IFN-α2b with ART for 20 weeks, with intermediate 4-week analytical ART interruption (ATI). Safety, immune activation, HIV viral load and integrated HIV DNA in blood, and HIV RNA and DNA in gut biopsies were measured...
June 2021: AIDS Research and Human Retroviruses